EP4054568A4 - Analogues de thiazolidinedione pour le traitement d'une nafld et de maladies métaboliques - Google Patents
Analogues de thiazolidinedione pour le traitement d'une nafld et de maladies métaboliques Download PDFInfo
- Publication number
- EP4054568A4 EP4054568A4 EP20884888.7A EP20884888A EP4054568A4 EP 4054568 A4 EP4054568 A4 EP 4054568A4 EP 20884888 A EP20884888 A EP 20884888A EP 4054568 A4 EP4054568 A4 EP 4054568A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- nafld
- treatment
- metabolic diseases
- thiazolidinedione analogs
- thiazolidinedione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000030159 metabolic disease Diseases 0.000 title 1
- 150000001467 thiazolidinediones Chemical class 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- G01N33/723—Glycosylated haemoglobin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/52—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving transaminase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Primary Health Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Data Mining & Analysis (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962933238P | 2019-11-08 | 2019-11-08 | |
US202063079905P | 2020-09-17 | 2020-09-17 | |
PCT/US2020/059548 WO2021092496A1 (fr) | 2019-11-08 | 2020-11-06 | Analogues de thiazolidinedione pour le traitement d'une nafld et de maladies métaboliques |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4054568A1 EP4054568A1 (fr) | 2022-09-14 |
EP4054568A4 true EP4054568A4 (fr) | 2023-12-13 |
Family
ID=75849629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20884888.7A Pending EP4054568A4 (fr) | 2019-11-08 | 2020-11-06 | Analogues de thiazolidinedione pour le traitement d'une nafld et de maladies métaboliques |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230013627A1 (fr) |
EP (1) | EP4054568A4 (fr) |
CN (1) | CN115279369A (fr) |
WO (1) | WO2021092496A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019213611A1 (fr) | 2018-05-04 | 2019-11-07 | Cirius Therapeutics, Inc. | Analogues de thiazolidinedione pour le traitement de nafld et de maladies métaboliques |
CN113913507A (zh) * | 2021-10-29 | 2022-01-11 | 温州医科大学附属第一医院 | Ccl3蛋白作为评估非酒精性脂肪性肝病炎症水平及疾病进展的生物标志物的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011133611A1 (fr) * | 2010-04-21 | 2011-10-27 | Metabolic Solutions Development Company | Analogues de thiazolidinedione |
WO2019213611A1 (fr) * | 2018-05-04 | 2019-11-07 | Cirius Therapeutics, Inc. | Analogues de thiazolidinedione pour le traitement de nafld et de maladies métaboliques |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120264824A1 (en) * | 2011-04-15 | 2012-10-18 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
US9486433B2 (en) * | 2012-10-12 | 2016-11-08 | Mochida Pharmaceuticals Co. Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
US9155513B2 (en) * | 2013-07-17 | 2015-10-13 | Hepatiq Llc | Systems and methods for determining hepatic function from liver scans |
-
2020
- 2020-11-06 CN CN202080092550.4A patent/CN115279369A/zh active Pending
- 2020-11-06 EP EP20884888.7A patent/EP4054568A4/fr active Pending
- 2020-11-06 WO PCT/US2020/059548 patent/WO2021092496A1/fr unknown
-
2022
- 2022-05-06 US US17/738,974 patent/US20230013627A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011133611A1 (fr) * | 2010-04-21 | 2011-10-27 | Metabolic Solutions Development Company | Analogues de thiazolidinedione |
WO2019213611A1 (fr) * | 2018-05-04 | 2019-11-07 | Cirius Therapeutics, Inc. | Analogues de thiazolidinedione pour le traitement de nafld et de maladies métaboliques |
Non-Patent Citations (3)
Title |
---|
HARRISON STEPHEN A ET AL: "Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study", JOURNAL OF HEPATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 72, no. 4, 4 November 2019 (2019-11-04), pages 613 - 626, XP086100852, ISSN: 0168-8278, [retrieved on 20191104], DOI: 10.1016/J.JHEP.2019.10.023 * |
KYLE S MCCOMMIS ET AL: "Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis", HEPATOLOGY, JOHN WILEY & SONS, INC, US, vol. 65, no. 5, 30 March 2017 (2017-03-30), pages 1543 - 1556, XP071562783, ISSN: 0270-9139, DOI: 10.1002/HEP.29025 * |
See also references of WO2021092496A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2021092496A1 (fr) | 2021-05-14 |
CN115279369A (zh) | 2022-11-01 |
US20230013627A1 (en) | 2023-01-19 |
EP4054568A1 (fr) | 2022-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3787618A4 (fr) | Analogues de thiazolidinedione pour le traitement de nafld et de maladies métaboliques | |
EP4031152A4 (fr) | Composés et compositions probiotiques pour le traitement de maladies et de troubles métaboliques | |
SG11202006374VA (en) | Treatment of demyelinating diseases | |
IL288375A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
IL279397A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
IL287796A (en) | Preparations and methods for the treatment of diseases mediated by ATPase | |
EP3971214A4 (fr) | Protéine de fusion destinée au traitement d'une maladie métabolique | |
SG11202010585WA (en) | New treatment of interstitial lung diseases | |
EP3801626A4 (fr) | Utilisation de comprimés orodispersibles à base de riluzole pour le traitement de maladies | |
GB201907558D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
EP4054568A4 (fr) | Analogues de thiazolidinedione pour le traitement d'une nafld et de maladies métaboliques | |
EP3877383A4 (fr) | Composés et compositions pour le traitement de maladies respiratoires | |
EP3866786A4 (fr) | Compositions et procédés de suppression et/ou de traitement de maladies métaboliques et/ou d'une affection clinique associée | |
EP3846821A4 (fr) | Polythérapie destinée au traitement d'une maladie hépatique | |
EP3619204A4 (fr) | Composés pour traiter des maladies respiratoires | |
EP3761982A4 (fr) | Traitement de maladies démyélinisantes | |
EP3744347A4 (fr) | Composition pour une utilisation dans le traitement de maladies cutanées | |
IL290927A (en) | The composition used to combat metabolic diseases and uses of the composition | |
IL285751A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
EP3846843A4 (fr) | Compositions et procédés de traitement de maladie cardiaque | |
EP3876946A4 (fr) | Compositions et méthodes pour le traitement d'une maladie artérielle périphérique et des maladies cardiopulmonaires | |
EP3755334A4 (fr) | Traitement de maladies hépatiques | |
EP3761981A4 (fr) | Traitement de maladies démyélinisantes | |
GB2603379B (en) | Avocatin B for the treatment of diseases and conditions | |
AU2018904242A0 (en) | Compounds and compositions for the treatment of respiratory diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220606 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40081415 Country of ref document: HK |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230514 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20231109 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G16H 50/20 20180101ALI20231103BHEP Ipc: G01N 33/72 20060101ALI20231103BHEP Ipc: C12Q 1/52 20060101ALI20231103BHEP Ipc: C07D 277/34 20060101ALI20231103BHEP Ipc: A61P 3/10 20060101ALI20231103BHEP Ipc: A61P 1/16 20060101ALI20231103BHEP Ipc: A61K 31/426 20060101AFI20231103BHEP |